Skip to main content

Branded

  • Actavis seeks FDA approval for contraceptive patch

    PARSIPPANY, N.J. — The Food and Drug Administration will review an experimental contraceptive patch made by Actavis, the drug maker said Tuesday.

    Actavis said the FDA accepted for review its application for norethindrone transdermal delivery system. The patch, which does not yet have a brand name, is designed to provide continuous delivery of norethindrone during a once-weekly, seven-day dosing regimen.

  • AstraZeneca encourages asthma awareness

    WILMINGTON, Del. — Drug maker AstraZeneca is encouraging patients with asthma to control their disease and learn about how it may be affecting their lives as part of National Asthma and Allergy Awareness Month, which takes place in May.

  • N.J. law designed to address prescription eye drop adherence

    TRENTON, N.J. — New Jersey Gov. Chris Christie signed legislation into law Monday that will allow patients using prescription eye drops to get early refills in order to prevent interruptions in therapy.

  • FDA approves Breo Ellipta for COPD

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for chronic obstructive pulmonary disease, the agency said Friday.

    The FDA announced the approval of Breo Ellipta (fluticasone furoate and vilanterol), a once-per-day inhaler made by GlaxoSmithKline and Theravance for long-term treatment of COPD, which includes chronic bronchitis and emphysema.

  • FDA approves Novartis' Ilaris for rare childhood arthritis

    EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.

  • Actavis in talks to combine with Warner Chilcott

    PARSIPPANY, N.J. — Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said Friday.

    Actavis, the world's third-largest generic drug maker, said it had entered into early-stage discussions with Warner Chilcott about a potential combination of the two, but that no agreement had been reached, and that it wouldn't issue further comment about the matter.

  • DEA collects more than 740,000 pounds of unused drugs

    WASHINGTON — The Drug Enforcement Administration collected more than 371 tons of unused medications last month as part of its sixth annual drug take-back program, the agency said.

  • Former Eli Lilly executive appointed to top technology post at Sears Holdings

    HOFFMAN ESTATES, Ill. — Sears Holdings has appointed Jeff Balagna as EVP and chief information officer, the Kmart parent company said Thursday.

    Balagna was previously chief information officer for drug maker Eli Lilly and will be responsible for Sears Holdings' technology and infrastructure initiatives in its support centers and in-store.

X
This ad will auto-close in 10 seconds